دورية أكاديمية
Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study
| العنوان: | Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study |
|---|---|
| المؤلفون: | Kocatürk, Emek, Salameh, Pascale, Sarac, Esra, Vera Ayala, Carolina E., Thomsen, Simon Francis, Zuberbier, Torsten, Ensina, Luis Felipe, Popov, Todor A., van Doorn, Martijn B.A., Giménez-Arnau, Ana Maria, Asero, Riccardo, Criado, Paulo Ricardo, Aarestrup, Fernando M., AbdulHameed Ansari, Zainab, Al Abri, Salma, Al Ahmad, Mona, Al Hinai, Bushra, Allenova, Anastasiia, Al-Nesf, Maryam, Altrichter, Sabine, Arnaout, Rand, BartosiÅ„ska, Joanna, Bauer, Andrea, Bernstein, Jonathan A., Bizjak, Mojca, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Calvalcanti Dela Bianca Melo, Ana Caroline, Campinhos, Fernanda L., Carne, Emily, Purayil, Saleema Cherichi, Cherrez-Ojeda, Ivan, Chong-Neto, Herberto Jose, Christoff, George, Conlon, Niall, Jardim Criado, Roberta Fachini, Cvenkel, Klara, Damadoglu, Ebru, Danilycheva, Inna, Day, Cascia, de Montjoye, Laurence, Demir, Semra, Ferucci, Silvia Mariel, Fomina, Daria, Fukunaga, Atsushi, Garcia, Elizabeth, Gelincik, Asli, Göbel, Joe Hannah, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Gugala, Agata, Guillet, Carole, Kalyoncu, Ali Fuat, Karakaya, Gul, Kasperska-ZajÄ…c, Alicja, Katelaris, Constance H., Khoshkhui, Maryam, Kleinheinz, Andreas, Kolacinska-Flont, Marta, Kolkhir, Pavel, KoÅ¡nik, Mitja, Krasowska, Dorota, Kumaran, Muthu Sendhil, Kuprys-Lipinska, Izabela, Kurowski, Marcin, Kuznetsova, Elizaveta V., Larenas-Linnemann, Désirée, Lebedkina, Marina S., Lee, Youngsoo, Makris, Michael P., Gómez, René Maximiliano, Nasr, Iman, Neisinger, Sophia, Oda, Yoshiko, Kara, Rabia ÖztaÅŸ, Palitot, Esther Bastos, Papapostolou, Niki, Salvador Parisi, Claudio Alberto, Pesque, David, Peter, Jonathan, Petkova, Elena, Ridge, Katie, Rudenko, Michael, Rutkowski, Krzysztof, Saini, Sarbjit S., Salman, Andac, Sanchez, Jorge, Åžekerel, Bülent, Serdotetskova, Sofia A., Serpa, Faradiba S., Dikicier, Bahar Sevimli, Sidiropoulos, Nikitas, Sikora, Agnieszka, Sørensen, Jennifer Astrup, Soria, Angele, Kucuk, Ozlem Su, Thalappil, Sherin Rahim, Tomaszewska, Katarzyna, Tuncay, Gulseren, Unal, Derya, Valle, Solange, van Lindonk, Esmee, Vestergaard, Christian, Vitchuk, Aleksandr, Xepapadaki, Paraskevi, Ye, Young-Min, Zalewska-Janowska, Anna, Zamlynski, Mateusz, Maurer, Marcus |
| المساهمون: | UCL - (SLuc) Service de dermatologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie |
| المصدر: | Journal of Allergy and Clinical Immunology, Vol. /, no./, p. / (2023) |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Immunology, Immunology and Allergy, Adverse effects, COVID-19, exacerbation, omalizumab |
| الوصف: | Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy. Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination. Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters. Results: Across 2769 COVID-19-vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination-induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination-induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine-related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions. Conclusions: COVID-19 vaccination leads to disease exacerbation in only a small ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0091-6749 |
| العلاقة: | boreal:278595; http://hdl.handle.net/2078.1/278595Test; urn:ISSN:0091-6749 |
| DOI: | 10.1016/j.jaci.2023.07.019 |
| الإتاحة: | https://doi.org/10.1016/j.jaci.2023.07.019Test http://hdl.handle.net/2078.1/278595Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.1B879DD1 |
| قاعدة البيانات: | BASE |
| تدمد: | 00916749 |
|---|---|
| DOI: | 10.1016/j.jaci.2023.07.019 |